Company intelligence / Profile preview

ChemAI

Leeds, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

ChemAI has commercialized AI-driven chemistry tools, collaborating with major pharma and biotech firms; its proprietary reaction database and platform enable significant improvements in synthetic route design, experiment optimization, and chemical R&D productivity with outcome prediction accuracy >90% in key transformations

Modalities: Small moleculeMachine learning/AI-driven predictive chemistry platform
Industry: Drug Discovery Services

Partnerships

Partners and clients include leading pharmaceutical, biotech, and cosmetic companies; no specific names disclosed in public sources

Beyond the preview

Go deeper on ChemAI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChemAI.

Explore the full profile